<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92312">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01903213</url>
  </required_header>
  <id_info>
    <org_study_id>KIK002</org_study_id>
    <nct_id>NCT01903213</nct_id>
  </id_info>
  <brief_title>Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)速 Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis</brief_title>
  <official_title>Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)速 Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of long-term use of Kiklin速 Capsules in actual clinical
      settings.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by the incidence of adverse events (including adverse drug reactions), vital signs and laboratory tests</measure>
    <time_frame>Baseline and 1, 2, 3, 6, 12 months after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum phosphorous levels</measure>
    <time_frame>Baseline and 1, 2, 3, 6, 12 months after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum albumin level</measure>
    <time_frame>Baseline and 1, 2, 3, 6, 12 months after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum calcium level</measure>
    <time_frame>Baseline and 1, 2, 3, 6, 12 months after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum intact PTH (parathyroid hormone) level</measure>
    <time_frame>Baseline and 1, 2, 3, 6, 12 months after administration</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>Kiklin group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kiklin capsules</intervention_name>
    <description>Oral</description>
    <arm_group_label>Kiklin group</arm_group_label>
    <other_name>AMG223</other_name>
    <other_name>ASP1585</other_name>
    <other_name>ILY101</other_name>
    <other_name>Bixalomer</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Chronic renal failure with Hyperphosphatemia receiving Peritoneal dialysis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic renal failure patients with Hyperphosphatemia receiving peritoneal dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Administration Dept.</last_name>
    <email>Astellas.registration@astellas.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tohoku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 27, 2017</lastchanged_date>
  <firstreceived_date>July 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peritoneal dialysis</keyword>
  <keyword>Bixalomer</keyword>
  <keyword>Chronic renal failure patients with Hyperphosphatemia</keyword>
  <keyword>Kiklin速</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
